Boston hosts 49th DIA meeting: drug development experts convene to address R&D strategies.
The exhibition features companies covering every aspect of the life sciences industry including CROs, IT vendors, research centers, academia. The conference program offers more than 250 sessions over 22 tracks on hot topics such as Biosimilars, Drug Shortages, Multiregional Clinical Trials, New Models of Innovation, Quality by Design Strategies, Risk Evaluation and Mitigation Strategies, and more.
Keynote, Daniel Kraft, MD, will present, Daniel Kraft on How Exponential Technologies Will Reboot Healthcare, Monday, June 24 at 8:30 a.m. Dr. Kraft has more than 20 years of experience in clinical practice, biomedical research and healthcare innovation. He chairs the Medicine track for Singularity University and is Executive Director for FutureMed, a program that explores convergent, exponentially developing technologies and their potential in biomedicine and healthcare.
Dr. Kraft was board certified in the Harvard combined Internal Medicine and Pediatrics residency program at the Massachusetts General and Boston Children's Hospital, and completed Stanford fellowships in hematology/oncology & bone marrow transplantation, and extensive research in stem cell biology and regenerative medicine.
He recently founded IntelliMedicine, focused on enabling connected, data driven, and integrated personalized medicine. He is also the inventor of the MarrowMiner, an FDA-approved device for the minimally invasive harvest of bone marrow, and founded RegenMed Systems, a company developing technologies to enable adult stem cell based regenerative therapies.
Plenary session, Big Data: Impact on Innovation, presented by Michael Rosenblatt, executive vice president and chief medical officer, Merck & Co.; Marc M. Boutin, JD, executive vice president and chief operating officer, National Health Council; and invited representatives from the European Medicines Agency. Tuesday, June 25, 10:15 a.m.-11:45 a.m.
Executive session, Reinventing the R&D Business Model: Heeding the President's PAST Report on Innovation, presented by Kenneth Getz, director of sponsored research, Tufts Center for Study of Drug Development; Bernard Munos, founder, InnoThink Center for Research in Biomedical Innovation; Tomasz Sablinski, founder of Transparency Life Sciences; Robert J. Franco, Ph.D., principal, PriceWaterhouseCoopers LLP; and Andy Lee, senior vice president, global clinical operations, Genzyme. Tuesday, June 25, 1:45 p.m.-3:15 p.m.
Plenary session, Advancing Alzheimer's Innovation: A Call to Action, presented by Peter Neumann, professor of Medicine, Institute for Clinical Research and Health Policy studies, Tufts Medical Center; Rudolph E. Tanzi, Ph.D., head, Genetics and Aging Research Unit, professor, Neurology, Harvard Medical School. Massachusetts General Hospital; George Vrandenburg, co-founder and president of USA ga instAlzheimer Wednesday, June 26, 10:15 a.m.-11:45 a.m.
Monday, June 24th 9:30 a.m.-5:30 p.m.
Welcome reception, 4:00 p.m.-5:30 p.m.
Tuesday, June 25th 9:00 a.m.-5:30 p.m.
Wednesday, June 26th 9:00 a.m.-4:00 p.m.
For more information visit: www.diahome.org